Revenue
27 thousand uref_1816609135
2026 Q2 · uref_1816609135
Exact inputs and evidence
- Revenue: 26955 uref_1816609135 Source
Fundies. English
OBALON THERAPEUTICS INC
EDGARAnnual consolidated revenue for 2025: about USD 319.7K, using the latest reported figures. The previous period, 2024, was about USD 256.9K.
Latest quarter
- Cash and cash equivalents
- 7.89 million uref_1816609135 Source
Exact value
7887510 uref_1816609135
- Long-term debt including current maturities
- 3 million Unit_Standard_USD_SJk73_-qBEmZg-8hUy_eHA Source
Exact value
3000000 Unit_Standard_USD_SJk73_-qBEmZg-8hUy_eHA
- Shares outstanding
- 7.02 million uref_258740382 Source
Exact value
7018528 uref_258740382
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-12.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 7 of 11 periods available· newest 2025-12-31
- Operating income: 7 of 11 periods available· newest 2025-12-31
- Net income: 7 of 11 periods available· newest 2025-12-31
- Operating cash flow: 7 of 11 periods available· newest 2025-12-31
- Capital expenditure: 2 of 11 periods available· newest 2020-12-31
- Total assets: Multiple units; comparison withheld· newest 2025-12-31
- Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
- Current assets: Multiple units; comparison withheld· newest 2025-12-31
- Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
- Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
- Long-term debt including current maturities: Multiple units; comparison withheld· newest 2020-12-31
- Shares outstanding: Multiple units; comparison withheld· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Revenue
+24.4%Prior period
USD 256,944
–
Current period
USD 319,714
–
Exact inputs and evidence
319714 − 256944 = 62770 USD
256944 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source319714 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 8.81 millionPrior period
−USD 1.45 million
–
Current period
−USD 10.26 million
–
Exact inputs and evidence
-10262007 − -1447461 = -8814546 USD
-1447461 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-10262007 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 3.13 millionPrior period
−USD 614,136
–
Current period
−USD 3.75 million
–
Exact inputs and evidence
-3748853 − -614136 = -3134717 USD
-614136 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-3748853 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2025 2025-01-01 – 2025-12-31
- Revenue USD 319,714 100% of revenue
- Cost of revenue USD 100,943 32% of revenue
- Operating expenses USD 10.67 million 3,338% of revenue
- Operating income −USD 10.45 million −3,269% of revenue
- Tax, interest and other Derived −USD 190,563 −60% of revenue
- Net income −USD 10.26 million −3,210% of revenue
Cash
- Operating cash flow −USD 3.75 million −1,173% of revenue
- Capital expenditure Unavailable An input is unavailable.
- Free cash flow Derived Unavailable An input is unavailable.
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2015 Operating loss: operating costs were 473% of revenue.
- 2016 Operating loss: operating costs were 674% of revenue.
- 2017 Operating loss: operating costs were 447% of revenue.
- 2018 Operating loss: operating costs were 506% of revenue.
- 2019 Operating loss: operating costs were 804% of revenue.
- 2024 Operating loss: operating costs were 492% of revenue.
- 2025 Operating loss: operating costs were 3,369% of revenue.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2015 2015-01-01 – 2015-12-31 | 4000000 | 18933000 Derived | -14933000 | 624000 Derived | -15557000 | Unavailable | Source
|
| 2016 2016-01-01 – 2016-12-31 | 3400000 | 22905000 Derived | -19505000 | 962000 Derived | -20467000 | Unavailable | Source
|
| 2017 2017-01-01 – 2017-12-31 | 9900000 | 44291000 Derived | -34391000 | 374000 Derived | -34765000 | Unavailable | Source
|
| 2018 2018-01-01 – 2018-12-31 | 9101000 | 46066000 Derived | -36965000 | 415000 Derived | -37380000 | Unavailable | Source
|
| 2019 2019-01-01 – 2019-12-31 | 3300000 | 26530000 Derived | -23230000 | 446000 Derived | -23676000 | Unavailable | Source
|
| 2024 2024-01-01 – 2024-12-31 | 256944 | 1263284 Derived | -1006340 | 441121 Derived | -1447461 | Unavailable | Source
|
| 2025 2025-01-01 – 2025-12-31 | 319714 | 10772284 Derived | -10452570 | -190563 Derived | -10262007 | Unavailable | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 319.7K 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2015 | Revenue | 4000000 |
|
| 2016 | Revenue | 3400000 |
|
| 2017 | Revenue | 9900000 |
|
| 2018 | Revenue | 9101000 |
|
| 2019 | Revenue | 3300000 |
|
| 2024 | Revenue | 256944 |
|
| 2025 | Revenue | 319714 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
24.4% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2015 | Year over year | No prior comparable period |
|
| 2016 | Year over year | -15% |
|
| 2017 | Year over year | 191.2% |
|
| 2018 | Year over year | -8.1% |
|
| 2019 | Year over year | -63.7% |
|
| 2024 | Year over year | No prior comparable period |
|
| 2025 | Year over year | 24.4% |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin -3,269.4% 2025
Net margin -3,209.7% 2025
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2015 | Operating margin | -373.3% |
|
| 2016 | Operating margin | -573.7% |
|
| 2017 | Operating margin | -347.4% |
|
| 2018 | Operating margin | -406.2% |
|
| 2019 | Operating margin | -703.9% |
|
| 2024 | Operating margin | -391.7% |
|
| 2025 | Operating margin | -3,269.4% |
|
| 2015 | Net margin | -388.9% |
|
| 2016 | Net margin | -602% |
|
| 2017 | Net margin | -351.2% |
|
| 2018 | Net margin | -410.7% |
|
| 2019 | Net margin | -717.5% |
|
| 2024 | Net margin | -563.3% |
|
| 2025 | Net margin | -3,209.7% |
|
| 2015 | Free cash flow margin | Not reported |
|
| 2016 | Free cash flow margin | Not reported |
|
| 2017 | Free cash flow margin | Not reported |
|
| 2018 | Free cash flow margin | Not reported |
|
| 2019 | Free cash flow margin | Not reported |
|
| 2024 | Free cash flow margin | Not reported |
|
| 2025 | Free cash flow margin | Not reported |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD -3.7M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2015 | Operating cash flow | -11392000 |
|
| 2016 | Operating cash flow | -19368000 |
|
| 2017 | Operating cash flow | -30624000 |
|
| 2018 | Operating cash flow | -29432000 |
|
| 2019 | Operating cash flow | -22866000 |
|
| 2024 | Operating cash flow | -614136 |
|
| 2025 | Operating cash flow | -3748853 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2015 | Free cash flow | Unavailable |
|
| 2016 | Free cash flow | Unavailable |
|
| 2017 | Free cash flow | Unavailable |
|
| 2018 | Free cash flow | Unavailable |
|
| 2019 | Free cash flow | Unavailable |
|
| 2024 | Free cash flow | Unavailable |
|
| 2025 | Free cash flow | Unavailable |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2015-12-31 | Liabilities / assets | Not reported | No source recorded |
| 2016-12-31 | Liabilities / assets | Not reported | No source recorded |
| 2017-12-31 | Liabilities / assets | Not reported | No source recorded |
| 2018-12-31 | Liabilities / assets | Not reported | No source recorded |
| 2019-12-31 | Liabilities / assets | Not reported | No source recorded |
| 2024-12-31 | Liabilities / assets | Not reported | No source recorded |
| 2025-12-31 | Liabilities / assets | Not reported | No source recorded |
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2015-12-31 | Current assets / current liabilities | Not reported | No source recorded |
| 2016-12-31 | Current assets / current liabilities | Not reported | No source recorded |
| 2017-12-31 | Current assets / current liabilities | Not reported | No source recorded |
| 2018-12-31 | Current assets / current liabilities | Not reported | No source recorded |
| 2019-12-31 | Current assets / current liabilities | Not reported | No source recorded |
| 2024-12-31 | Current assets / current liabilities | Not reported | No source recorded |
| 2025-12-31 | Current assets / current liabilities | Not reported | No source recorded |
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2015 2015-01-01 – 2015-12-31 | −USD 15.56 million Exact valueExact value: -15557000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 11.39 million Exact valueExact value: -11392000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2016 2016-01-01 – 2016-12-31 | −USD 20.47 million Exact valueExact value: -20467000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 19.37 million Exact valueExact value: -19368000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2017 2017-01-01 – 2017-12-31 | −USD 34.77 million Exact valueExact value: -34765000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 30.62 million Exact valueExact value: -30624000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2018 2018-01-01 – 2018-12-31 | −USD 37.38 million Exact valueExact value: -37380000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 29.43 million Exact valueExact value: -29432000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2019 2019-01-01 – 2019-12-31 | −USD 23.68 million Exact valueExact value: -23676000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 22.87 million Exact valueExact value: -22866000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | −USD 1.45 million Exact valueExact value: -1447461 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 614,136 Exact valueExact value: -614136 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −USD 10.26 million Exact valueExact value: -10262007 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 3.75 million Exact valueExact value: -3748853 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
84 filings · 5,725 latest values · 5,725 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001427570, 1427570, HIND, OBLN, RSLS, edgar:1427570
Also known as OBALON THERAPEUTICS INC, RESHAPE LIFESCIENCES INC., RESHAPE LIFESCIENCES INC., ReShape Lifesciences Inc., VYOME HOLDINGS, INC., Vyome Holdings, Inc, Vyome Holdings, Inc.